You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 17, 2024

Investigational Drug Information for Solabegron

✉ Email this page to a colleague

« Back to Dashboard

What is the drug development status for Solabegron?

Solabegron is an investigational drug.

There have been 8 clinical trials for Solabegron. The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2006.

The most common disease conditions in clinical trials are Urinary Bladder, Overactive, Irritable Bowel Syndrome, and Syndrome. The leading clinical trial sponsors are GlaxoSmithKline, Velicept Therapeutics, Inc., and [disabled in preview].

Recent Clinical Trials for Solabegron
A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001)Velicept Therapeutics, Inc.Phase 2
Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult WomenVelicept Therapeutics, Inc.Phase 2
Evaluate the Safety, Tolerability and PK of Different Formulations of Orally Administered Solabegron in Healthy Male SubjectsVelicept Therapeutics, Inc.Phase 1

See all Solabegron clinical trials

Clinical Trial Summary for Solabegron

Top disease conditions for Solabegron
Top clinical trial sponsors for Solabegron

See all Solabegron clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.